HMGB1 as a potential new marker of disease activity in patients with multiple sclerosis.
Maria BucovaBeata MajernikovaVladimira DurmanovaDaniela CudrakovaKarin GmitterovaIveta LisaEleonora KlimovaKristina KluckovaMilan BucPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2019)
Our results suggest chronic low-grade inflammation in MS patients that correlates with clinical conditions of MS patients, and for HMGB1 as a possible target molecule in future therapy.
Keyphrases
- end stage renal disease
- low grade
- disease activity
- chronic kidney disease
- newly diagnosed
- ejection fraction
- systemic lupus erythematosus
- multiple sclerosis
- mass spectrometry
- rheumatoid arthritis
- prognostic factors
- peritoneal dialysis
- oxidative stress
- ms ms
- stem cells
- rheumatoid arthritis patients
- patient reported outcomes
- ankylosing spondylitis
- climate change
- human health